Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production ...(Company plans to scale-up vaccine produc...),Health

Date:12/20/2007

Company plans to scale-up vaccine production at its Belleville facility over the next two years to provide capacity of 40 million doses of the E. coli O157:H7 vaccine. The scale-up is expected to cost approximately $25 million, and is part of a long-term, $100 million project to create an Animal Health and Food Safety Vaccine Manufacturing Centre. Financing of $10 million from the Ministry of Economic Development and Trade (MEDT)'s Advanced Manufacturing Investment Strategy (AMIS) was announced earlier this week. The remainder of the $25 million for the first phase of scale-up is in the process of being secured from other sources, the details of which will be announced when finalized.

"This federal government funding recognizes the potential of our E. coli O157:H7 cattle vaccine as an enhancement to the Canadian agricultural sector," said Graeme McRae, President & CEO of Bioniche Life Sciences Inc. "Adoption of this vaccine will provide an additional stamp of safety for Canadian agricultural products at home and abroad, particularly for our beef."

It remains very clear that there is a pressing need to reduce the amount of E. coli O157:H7 shed into the environment by cattle. Food recalls continue to occur on a massive scale in beef, produce and prepared food: Just from September, North American E. coli O157:H7-related recalls have totalled 22.7 million pounds of beef, multiple lots of packaged greens and five million frozen pizzas. On-farm interventions to reduce the shedding of E. coli O157:H7 by cattle, such as vaccination, may assist in reducing the potential for food and water contamination and the resulting human illnesses and deaths.

Approximately 100,000 cases of human infection with the E. coli O157:H7 organism are reported each year in North America. 2% to 7% of those people develop hemolytic uremic syndrome (HUS), a disease characterized by kidney failure (in recent outbreaks, this percentage has risen to as high as 16%). Five percent o
'/>"/>

SOURCE Bioniche Life Sciences Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Bioniche Responds to Australian Equine Influenza Outbreak
2. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
3. Bioniche Food Safety Vaccine Receives Global Top Honours in Industry Excellence Awards
4. Bioniche Receives Comment from USDA on a Field Trial for E. coli O157:H7 Cattle Vaccine
5. Media Advisory - Bioniche Discusses USDA Comment on E. coli O157:H7 Cattle Vaccine Field Trial
6. Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference
7. Bioniche Reports Fiscal 2008 First Quarter
8. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
9. DaVita Receives Civil Complaint
10. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
11. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility